Company Description
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields.
Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Aug 21, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 238 |
| CEO | Nello Mainolfi |
Contact Details
Address: 500 North Beacon Street, 4th Floor Watertown, Massachusetts 02472 United States | |
| Phone | 857 285 5300 |
| Website | kymeratx.com |
Stock Details
| Ticker Symbol | KYMR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 1815442 |
| CUSIP Number | 501575104 |
| ISIN Number | US5015751044 |
| Employer ID | 81-2992166 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder and Independent Chairman |
| Bruce N. Jacobs CFA | Chief Financial Officer |
| Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer |
| Dr. Jared A. Gollob M.D. | Chief Medical Officer |
| Justine E. Koenigsberg | Vice President of Investor Relations |
| Brian R. Adams J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Neil Graham M.D., M.P.H., MBBS | Chief Development Officer |
| Karen Weisbach | Head of People and Culture |
| Dr. Juliet Williams B.A Ph.D. | Head of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 424B3 | Prospectus |
| Feb 26, 2026 | 424B5 | Filing |
| Feb 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 26, 2026 | 10-K | Annual Report |